We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The latest trading session saw Abbott (ABT - Free Report) ending at $114.31, denoting a +0.07% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of 0.73%. Meanwhile, the Dow experienced a rise of 0.16%, and the technology-dominated Nasdaq saw an increase of 0.98%.
Shares of the maker of infant formula, medical devices and drugs have depreciated by 3% over the course of the past month, outperforming the Medical sector's loss of 3.8% and lagging the S&P 500's gain of 0.34%.
Market participants will be closely following the financial results of Abbott in its upcoming release. On that day, Abbott is projected to report earnings of $1.34 per share, which would represent year-over-year growth of 12.61%. At the same time, our most recent consensus estimate is projecting a revenue of $11.02 billion, reflecting a 7.64% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $4.67 per share and a revenue of $42 billion, representing changes of +5.18% and +4.71%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Abbott. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Abbott presently features a Zacks Rank of #2 (Buy).
From a valuation perspective, Abbott is currently exchanging hands at a Forward P/E ratio of 24.45. For comparison, its industry has an average Forward P/E of 25.12, which means Abbott is trading at a discount to the group.
We can additionally observe that ABT currently boasts a PEG ratio of 2.69. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.29.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 124, this industry ranks in the top 50% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott (ABT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
The latest trading session saw Abbott (ABT - Free Report) ending at $114.31, denoting a +0.07% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of 0.73%. Meanwhile, the Dow experienced a rise of 0.16%, and the technology-dominated Nasdaq saw an increase of 0.98%.
Shares of the maker of infant formula, medical devices and drugs have depreciated by 3% over the course of the past month, outperforming the Medical sector's loss of 3.8% and lagging the S&P 500's gain of 0.34%.
Market participants will be closely following the financial results of Abbott in its upcoming release. On that day, Abbott is projected to report earnings of $1.34 per share, which would represent year-over-year growth of 12.61%. At the same time, our most recent consensus estimate is projecting a revenue of $11.02 billion, reflecting a 7.64% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $4.67 per share and a revenue of $42 billion, representing changes of +5.18% and +4.71%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Abbott. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Abbott presently features a Zacks Rank of #2 (Buy).
From a valuation perspective, Abbott is currently exchanging hands at a Forward P/E ratio of 24.45. For comparison, its industry has an average Forward P/E of 25.12, which means Abbott is trading at a discount to the group.
We can additionally observe that ABT currently boasts a PEG ratio of 2.69. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.29.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 124, this industry ranks in the top 50% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.